Literature DB >> 12357474

Teratogen-induced limb defects.

Lewis B Holmes1.   

Abstract

Limb abnormalities are one of the most common and visible phenotypic effects of several human teratogens. The specific effects are different for most teratogens and include effects on limb morphogenesis (thalidomide, warfarin, phenytoin, valproic acid) and the effect of vascular disruption on a limb that had formed normally (misoprostol, chorionic villus sampling, and phenytoin). Either duplication (preaxial polydactyly of hands and feet) or deficiency (absence of thumb) is a common effect of thalidomide; no other human teratogen identified to date has this effect on the developing limb. Procedures during pregnancy, including chorionic villus sampling and dilation and curettage, produce defects of vascular disruption. For common exposures, such as alcohol and cocaine, it has been difficult to confirm objectively the exposure during embryogenesis and to ascribe specific limb defects that are produced. The molecular basis for the limb defects produced by the recognized human teratogens remains unknown. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12357474     DOI: 10.1002/ajmg.10781

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  16 in total

1.  Why study human limb malformations?

Authors:  Andrew O M Wilkie
Journal:  J Anat       Date:  2003-01       Impact factor: 2.610

2.  Extending the clinical spectrum of pain channelopathies.

Authors:  Henry Houlden
Journal:  Brain       Date:  2012-02       Impact factor: 13.501

Review 3.  Sirenomelia: an epidemiologic study in a large dataset from the International Clearinghouse of Birth Defects Surveillance and Research, and literature review.

Authors:  Iêda M Orioli; Emmanuelle Amar; Jazmin Arteaga-Vazquez; Marian K Bakker; Sebastiano Bianca; Lorenzo D Botto; Maurizio Clementi; Adolfo Correa; Melinda Csaky-Szunyogh; Emanuele Leoncini; Zhu Li; Jorge S López-Camelo; R Brian Lowry; Lisa Marengo; María-Luisa Martínez-Frías; Pierpaolo Mastroiacovo; Margery Morgan; Anna Pierini; Annukka Ritvanen; Gioacchino Scarano; Elena Szabova; Eduardo E Castilla
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-10-14       Impact factor: 3.908

4.  Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.

Authors:  Xuelin Dou; Yazhen Qin; Xiaojun Huang; Qian Jiang
Journal:  Oncologist       Date:  2019-06-11

5.  Maternal periconceptional alcohol consumption and congenital limb deficiencies.

Authors:  Kristin M Caspers Conway; Paul A Romitti; Lewis Holmes; Richard S Olney; Sandra D Richardson
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-08-18

6.  Antioxidant Consumption is Associated with Decreased Odds of Congenital Limb Deficiencies.

Authors:  Nelson D Pace; Tania A Desrosiers; Suzan L Carmichael; Gary M Shaw; Andrew F Olshan; Anna Maria Siega-Riz
Journal:  Paediatr Perinat Epidemiol       Date:  2017-09-04       Impact factor: 3.980

7.  Autism with ophthalmologic malformations: the plot thickens.

Authors:  Marilyn T Miller; Kerstin Strömland; Liana Ventura; Maria Johansson; Jose M Bandim; Christopher Gillberg
Journal:  Trans Am Ophthalmol Soc       Date:  2004

8.  Maternal caffeine consumption and risk of congenital limb deficiencies.

Authors:  Lei Chen; Erin M Bell; Marilyn L Browne; Charlotte M Druschel; Paul A Romitti; Rebecca J Schmidt; Trudy L Burns; Roxana Moslehi; Richard S Olney
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2012-08-18

Review 9.  Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research.

Authors:  Kevin G Bath; Helen E Scharfman
Journal:  Epilepsy Behav       Date:  2013-01-08       Impact factor: 2.937

10.  Limited surface examination to evaluate potential teratogens in a resource-limited setting.

Authors:  Lewis B Holmes; Hanah Z Nasri; Anne-Therese Hunt; Rebecca Zash; Roger L Shapiro
Journal:  Birth Defects Res       Date:  2021-03-28       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.